Needham Reiterates Buy on Cytokinetics, Maintains $102 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.5%

Neg 0% Neu 90.5% Pos 0%

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $102 price target.

Comments

No comments yet. Be the first!